These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26676391)

  • 21. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil.
    Tanuma Y; Tanaka Y; Okamoto T
    Urol Ann; 2021; 13(3):296-300. PubMed ID: 34421268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.
    Masumori N
    Ther Clin Risk Manag; 2011; 7():227-38. PubMed ID: 21753885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
    Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
    Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study.
    Tanuma Y; Tanaka Y; Takeyama K; Okamoto T
    Urol Ann; 2017; 9(3):261-267. PubMed ID: 28794594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia.
    Morita T; Kubo KK; Fujisaki A; Natsui S; Nukui A; Kobayashi M; Kurokawa S
    Res Rep Urol; 2013; 5():83-90. PubMed ID: 24400239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia.
    Sakuma T; Sato K; Nagane Y; Mochida J; Sugimoto S; Ichinose T; Yamaguchi K; Uchiyama M; Takahashi S
    Low Urin Tract Symptoms; 2010 Sep; 2(2):119-22. PubMed ID: 26676294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Alpha 1 Adrenoceptor Antagonist Dose Increase Therapy: An Essential Strategy for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Watanabe M; Yamaguchi S; Kakizaki H; Hirabayashi N; Ishida H
    Curr Urol; 2020 Oct; 14(3):113-121. PubMed ID: 33224003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of naftopidil in the management of benign prostatic hyperplasia.
    Hara N; Mizusawa T; Obara K; Takahashi K
    Ther Adv Urol; 2013 Apr; 5(2):111-9. PubMed ID: 23554846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
    Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
    Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
    Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
    Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement.
    Perumal C; Chowdhury PS; Ananthakrishnan N; Nayak P; Gurumurthy S
    Urol Ann; 2015; 7(1):74-8. PubMed ID: 25657550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Doxazosin on Alpha 1-Adrenergic Receptors in Prostates with Benign Prostatic Hyperplasia.
    Lee HN; Lee KS; Lee SY; Shim BS; Lee YS; Hong JH; Lim BH; Lee HM
    Low Urin Tract Symptoms; 2013 May; 5(2):82-9. PubMed ID: 26663375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study].
    Masuda M; Jinza S; Masuko H; Asakura T; Hashiba T
    Hinyokika Kiyo; 2012 Dec; 58(12):671-8. PubMed ID: 23328162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Additional Dutasteride on Lower Urinary Tract Symptoms in Patients with Alpha-1 Blocker-Resistant Benign Prostatic Hyperplasia.
    Sengiku A; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
    Low Urin Tract Symptoms; 2013 Sep; 5(3):159-63. PubMed ID: 26663453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.